Verona Pharma
plc
("Verona Pharma" or the
"Company")
Appointment of
Vikas Sinha as Non-Executive Director
12 September 2016, Cardiff
– Verona Pharma plc (AIM: VRP), a drug development company focused
on first-in-class medicines to treat respiratory diseases, today
announces the appointment of Vikas Sinha to the Board of Verona
Pharma as a Non-Executive Director, with immediate effect.
Vikas (aged 53) has over 20 years of experience working in
senior finance roles in the life sciences industry. He is currently
Executive Vice President and Chief Financial Officer of Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), one of the world's leading
rare disease companies with a market cap of approximately
USD30 billion. Vikas joined Alexion
in 2005 and is responsible for global financial management,
information technology, corporate and strategic development,
treasury, internal audit and investor relations.
Prior to Alexion, Vikas spent 11 years at Bayer AG where he held
various positions within the company in the United States, Canada,
Japan and Germany. His last role was Vice President and Chief
Financial Officer of Bayer Pharmaceuticals Corporation, USA, where
he was responsible for financial management and strategic planning
in North America.
Prior to his time at Bayer AG, Vikas worked at ANZ Bank as a
Senior Manager in Corporate Banking and at Citibank as an
analyst.
Vikas is a chartered accountant by training. He is a certified
public accountant in the USA, and an associate member of the
Institute of Chartered Accountants of India. Vikas also has a
Master’s degree in Business Administration from the Asian Institute
of Management in the Philippines.
Dr. David Ebsworth, Chairman of Verona Pharma, said: “Vikas’
impressive financial background, including his US expertise,
makes him a very welcome addition to our Board of Directors. I have
known Vikas for many years having worked together at Bayer and hold
his impressive track record in high regard. We are pleased that
Vikas will be joining our Board at such a pivotal time, as we
progress our lead asset, RPL554, into a Phase 2b clinical trial
programme.”
Schedule Two
information regarding Vikas Sinha
Vikas Sinha holds or has held the following directorships and
partnerships in the last five years:
Current Directorships
memberships: |
Past Directorships memberships: |
|
|
Alexion Pharma Holding |
Stemcentrx Inc. |
Save for the information disclosed above, there is no other
information in relation to Vikas required to be disclosed
pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies.
-Ends-
For further information please
contact:
Verona Pharma plc |
Tel: +44 (0) 20 3283
4200 |
Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biotech company
focused on the development of innovative prescription medicines to
treat respiratory diseases with significant unmet medical needs,
such as chronic obstructive pulmonary disease (COPD), asthma and
cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised maintenance treatment
for COPD patients with moderate to severe disease and possibly as a
treatment of acute exacerbations of COPD in the hospital setting.
The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and
therefore has both bronchodilator and anti-inflammatory effects,
which are essential to the improvement of patients with COPD and
asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD and
asthma maintenance therapy. The Company is also exploring the
potential of the drug in different diseases, such as cystic
fibrosis, where it is in pre-clinical testing and has recently
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.